Understanding what to eat while taking Ozempic® (semaglutide), Wegovy® (semaglutide), or compounded semaglutide is crucial for maximizing weight loss benefits. This guide will provide a comprehensive list of foods to eat while on semaglutide and highlight the … Read more
FDA notice on Zepbound™/Mounjaro® shortage: On December 19th, 2024, the U.S. Food and Drug Administration determined that the shortage of tirzepatide injection, a glucagon-like peptide 1 (GLP-1) medication, has ended. Patients may continue receiving essential copies through … Read more
FDA notice on Zepbound®/Mounjaro® shortage: The U.S. Food and Drug Administration has determined the shortage of tirzepatide injection, a glucagon-like peptide 1 (GLP-1) medication, has ended. Schedule a visit with an Ivim provider to discuss what this … Read more
At Ivím Health, our mission is to deliver unparalleled, personalized care that goes far beyond basic healthcare—and our membership model allows us to do just that. We’re proud to offer so much more than just weight loss … Read more
Elevating Workplace Wellness Through Clinically Crafted Solutions COLUMBUS, Ohio, July 8, 2024 — Ivim Health, a leading provider of GLP-1 weight loss programs, is launching Ivim at Work. This first-of-its-kind corporate wellness program, focused on optimizing weight management and … Read more
FDA notice on Wegovy®/Ozempic® shortage: On February 21st, 2025, the U.S. Food and Drug Administration determined that the shortage of semaglutide injection, a glucagon-like peptide 1 (GLP-1) medication, has ended. Patients may continue receiving essential copies through … Read more
At Ivím, our mission is to build health and foster community, not just within our own organization, but across the globe. We are proud to have dedicated providers like Arielle Gelardi, NP, who embody this mission through … Read more
FDA notice on Zepbound®/Mounjaro® shortage: On October 2, 2024, the U.S. Food and Drug Administration determined that the shortage of tirzepatide injection, a glucagon-like peptide 1 (GLP-1) medication, had ended. (Read more) Schedule a visit with an Ivim … Read more
Initially developed as a treatment for type 2 diabetes, Ozempic® (semaglutide) has emerged as a transformative solution for weight loss. Semaglutide, the active ingredient in Ozempic®, has shown significant results in clinical trials. Research reveals that adults … Read more
FDA notice on Zepbound®/Mounjaro® shortage: On October 2, 2024, the U.S. Food and Drug Administration determined that the shortage of tirzepatide injection, a glucagon-like peptide 1 (GLP-1) medication, had ended. (Read more) Schedule a visit with an Ivim … Read more
